Repeated need for rapid tranquillisation · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviours ‐ threat or injury to others/self compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcomes ‐ overall improvement · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower global outcomes ‐ overall improvement compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Leaving the study early · people with long‐term aggression in psychosis
HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Economic outcomes · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects dystonia ‐ short term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Service use and hospitalisation: admission ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: Change over time ‐ no better or deterioration ‐ short and medium term as defined in each study · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes global state: Change over time ‐ no better or deterioration ‐ short… compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state: State ‐ 'no effect' BPRS score reduction · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes mental state: State ‐ 'no effect' BPRS score reduction compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · schizophrenia
Lithium showed no clear difference in clinically significant response on depressive symptoms at least 50%… compared with antipsychotics (low certainty).
1 finding from 1 review
Clinically significant response on manic symptoms at least 50% Bech‐Rafaelsen improvement · schizophrenia
Lithium showed no clear difference in clinically significant response on manic symptoms at least 50%… compared with antipsychotics (low certainty).
1 finding from 1 review
Clinically significant response on positive symptoms at least 50% MS improvement · schizophrenia
Lithium may leads to lower clinically significant response on positive symptoms at least 50% MS… compared with antipsychotics (low certainty).
1 finding from 1 review
Kidney dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Response to treatment clinically relevant response as defined by the authors · schizophrenia
Lithium showed no clear difference in response to treatment clinically relevant response as defined by the… compared with antipsychotics (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · schizophrenia
It is very uncertain whether lithium changes acceptability of treatment leaving early due to any reason compared with antipsychotics (very low certainty).
1 finding from 1 review